{"id":"NCT02369159","sponsor":"BioCryst Pharmaceuticals","briefTitle":"Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza","officialTitle":"A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-11","primaryCompletion":"2019-10-28","completion":"2020-05-14","firstPosted":"2015-02-23","resultsPosted":"2021-03-23","lastUpdate":"2021-03-23"},"enrollment":137,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Peramivir","otherNames":[]},{"type":"DRUG","name":"Oseltamivir","otherNames":[]}],"arms":[{"label":"Peramivir (IV)","type":"EXPERIMENTAL"},{"label":"Oseltamivir","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated influenza.","primaryOutcome":{"measure":"Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.","timeFrame":"14 days","effectByArm":[{"arm":"Peramivir","deltaMin":22,"sd":null},{"arm":"Oseltamivir","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"0 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Vomiting","Diarrhoea","Nausea","Pyrexia","Tympanic membrane hyperaemia"]}}